Class / Patent application number | Description | Number of patent applications / Date published |
514032000 | Oxygen of the saccharide radical bonded to a nonsaccharide hetero ring by acyclic carbon bonding | 33 |
20080261901 | Cosmetic Composition Comprising Beta-Fructosyl-L-Ascorbic Acid for Skin Whitening - The present invention is related to novel cosmetic composition comprising β-fructosyl-L-ascorbic acid derivatives produced by fructose conversion reaction using by ascorbic acid and the compounds shows potent inhibiting effect on the activity of tyrosinase enzyme, therefore, it can be useful as a skin whitening cosmetic composition as an cream, skin, lotion, pack and the like. | 10-23-2008 |
20090042816 | Synthetic Ligands For The Differentiation Of Closely Related Toxins And Pathogens - Synthetic ligand compounds and methods of differentiating between Shiga toxin 1 and Shiga toxin 2 are disclosed herein. Another embodiment includes a kit for differentiating between Shiga toxin 1 and Shiga toxin 2. Assay systems and methods for providing an assay are also provided for herein. | 02-12-2009 |
20090048186 | Monosaccharide Derivatives as Anti-Inflammatory and/or Anti-Cancer Agents - The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis and allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided. | 02-19-2009 |
20090215707 | COMPOUND HAVING CYCLIC STRUCTURE AND USE THEREOF - The present invention relates to a compound represented by the following formula (1′) | 08-27-2009 |
20090291904 | CHEMICAL DERIVATIVES OF JASMONATE, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF - The present invention relates to novel jasmonate derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for prevention and treatment of cancers. | 11-26-2009 |
20100009925 | 18-MEMBERED MACROCYCLES AND ANALOGS THEREOF - The present invention relates generally to the 18-membered macrocyclic antimicrobial agents called Tiacumicins, specifically, OPT-80 (which is composed almost entirely of the R-Tiacumicin B), pharmaceutical compositions comprising OPT-80, and methods using OPT-80. In particular, this compound is a potent drug for the treatment of bacterial infections, specifically | 01-14-2010 |
20100093651 | Artemisinin Derivatives - This disclosure provides improved derivatives of artemisinin; pharamaceutical compositions containing these compounds; methods for preparing these compounds and compositions; methods of using these compounds and compositions for preventing, controlling or treating infectious diseases including but not limited to parasitic infectious diseases such as | 04-15-2010 |
20100093652 | Preservative System for Emulsion-Based Therapeutic Topical Formulations - A topical formulation that inhibits the growth of microorganisms comprises an effective amount of an insecticide dissolved in an oil phase comprising a water-miscible or water-soluble surface active agent, a suspending agent, and a non-ionic surfactant, and an aqueous phase comprising one or more preservatives, where the aqueous phase is buffered to a specific pH. The overall antimicrobial efficacy in an emulsion formulation can be enhanced by buffering the aqueous phase of the emulsion to a pH at which the preservative system inhibits growth for a wider variety of microorganism types in the formulation relative to the equivalent formulation in which the aqueous phase is not buffered. | 04-15-2010 |
20100099636 | HYDROUS GEL AND PRODUCTION PROCESS AND USE OF THE HYDROUS GEL - A hydrous gel substantially comprising at least two polymers selected from the group consisting of polyacrylic acid, sodium polyacrylate and partially neutralized polyacrylate, and water, the polymers being crosslinked by containing an aluminum compound, wherein the pH when the hydrous gel is 100-fold diluted with purified water is from 6.5 to 8.5. A hydrous gel which can stably hold an ascorbic acid or a derivative thereof, has high gel strength, exhibits good adhesion to an adherend and causes no liquid syneresis can be provided. | 04-22-2010 |
20100173860 | Purifications of Pomegranate Ellagitannins and Their Uses Thereof - Compositions of purified and biologically active ellagitannins are provided by separation from pomegranate husk using a method of extraction and purification using a solid polymeric adsorbent and the uses of the said compounds | 07-08-2010 |
20100298248 | BIOLOGICALLY ACTIVE MACROLIDES, COMPOSITIONS, AND USES THEREOF - The present invention provides a compound of the formula (I) or (II, wherein R | 11-25-2010 |
20110071097 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF - The present invention provides novel cephalotaxus esters, syntheses thereof, and intermediates thereto. The invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of using said compounds or compositions in the treatment of proliferative diseases (e.g., benign neoplasm, cancer, inflammatory disease, autoimmune disease, diabetic retinopathy) and infectious disease. The invention further provides methods of using said compounds or compositions in the treatment of multidrug resistant cancer. | 03-24-2011 |
20110098240 | PHARMACEUTICAL COMPOSITION COMPRISING A SGLT2 INHIBITOR IN COMBINATION WITH A DPP-IV INHIBITOR - The invention relates to a pharmaceutical composition according to claim | 04-28-2011 |
20110224158 | ESTERIFIED ALPHA-GALACTOSYLCERAMIDE - The invention provides esterified α-galactosylceramides effective for cancer treatment and the like, and a medicament containing same. In particular, the invention relates to a compound represented by the formula (I): | 09-15-2011 |
20120101054 | Novel Sodium Channel Blocking Compounds Tetrodotoxin Galactopyranosides - Novel sodium channel blocking compounds tetrodotoxm galactopyranosides of formula I were isolated and purified by HPLC and identified further through IR, NMR, GC, and MS. The compounds have a galactopyranosyl moiety attached to C11 of tetrodotoxin and retain the analgesic activity of the latter. Pharmaceutical compositions and medical uses thereof are further disclosed. | 04-26-2012 |
20120214756 | COOPERATIVE CONVEYANCE OF BASIC ACTIVE PRINCIPLES BY AMPHIPHILIC ACID MOLECULES - The present invention relates to an intermolecular association complex of an amphiphilic carrier and an active principle G, having the following general formula (I), as well as to the compositions containing same, to the uses thereof, particularly as a drug, and to the method for preparing same. | 08-23-2012 |
20120258924 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM - Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system. | 10-11-2012 |
20120329743 | CYCLOALKYL-FUSED TETRAHYDROQUINOLINES AS CRTH2 RECEPTOR MODULATORS - The invention provides certain cycloalkyl-fused tetrahydroquinolines of the Formula (I), | 12-27-2012 |
20130178435 | Diagnostic Methods for Hematological Disorders - Provided are methods for prognosing a clinical outcome in a subject with a hematological disorder comprising determining a 3D telomeres organization signature of a test sample cell from the subject, wherein the 3D telomeres organization signature of the test sample cell is indicative of the clinical outcome of the subject. | 07-11-2013 |
20130281393 | MATERIALS AND METHODS FOR PREVENTION AND TREATMENT OF VIRAL INFECTIONS - The present invention provides novel and advantageous materials and methods for preventing and treating viral infection. | 10-24-2013 |
20130310331 | ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID - There is provided an antidiabetic enolic glucoside of phenylpyruvic acid and derivatives thereof for use as medicaments, especially normoglycemic agents, i.e. for lowering blood glucose levels to normal levels in mammals that are obese, pre-diabetic or have diabetes, obesity and/or syndrome X. Hence the compounds of the present invention help to manage blood sugar levels, i.e. helping the body by balancing the blood sugar levels; helping to keep balanced blood glucose levels, particularly in humans with diabetes; aiding by enhancing the glucose uptake by the cells and by reducing sugar levels, thus improving or restoring the glucose tolerance; optimizing the glycemic response; normalizing the glucose tolerance. | 11-21-2013 |
20130331349 | COMPOSITIONS AND METHODS FOR MODULATING FXR - The present invention relates to compounds of Formula (I), a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesiod X receptors (FXR). | 12-12-2013 |
20140187507 | TREATMENT OF PARKINSONS DISEASE WITH GLYCOLIPIDS - This invention provides compounds, compositions, and methods for treating Parkinson's disease. In particular, there is provided GM1 ganglioside analogs that are capable of penetrating the blood brain barrier and entering the cytoplasm of neurons. Endogenous GM1 interacts with the with GFRα1/RET, the GDNF receptor complex involved in GDNF signaling which is essential for neuron survival. In neurons that are deficient in endogenous GM1, the GM1 analog compounds of the invention are capable of restoring GDNF signaling thereby preventing neuron cell death. | 07-03-2014 |
20140309182 | INSECTICIDAL COMPOUNDS FROM NOTHAPODITES FOETIDA AND PROCESS FOR THE EXTRACTION THEREOF - The present invention relates to an insecticidal enriched extract (biopesticide) isolated from the stem of | 10-16-2014 |
20140349955 | USE OF FLUORINE-CONTAINING WATER SOLUBLE PLATINUM COMPLEX IN PREPARING DRUGS FOR PREVENTION AND TREATMENT OF CANCERS - Disclosed in the present invention is the use of a fluorine-containing in preparing drugs for the prevention and treatment of tumors, said platinum complex being shown as formula (I). Experiments have demonstrated that the present fluorine-containing water soluble platinum complex is highly water soluble and exhibiting superior cytotoxicity and efficacy compare to the clinical platinum drugs. Said complex alone or in combination with other chemotherapeutics is able to treat cancer in mammals, and in particular, humans, said cancers including lung cancer, colon cancer, head and neck cancer, prostate cancer, breast cancer, ovarian cancer, cervical cancer, leukemia, lymphoid cancer, skin cancer, pancreatic cancer, liver cancer, bladder cancer, esophageal cancer, gastric cancer, male genital cancer or bone cancer. | 11-27-2014 |
20140364386 | Small Molecule Compounds That Control Plant- and Insect-Pathogenic Nematodes - The present invention relates to methods of modifying nematode behavior using certain isolated modulator compounds. Also disclosed are methods of promoting or inhibiting reproduction in a nematode population, methods of promoting or inhibiting nematode aggregation at a first location, and methods of treating or preventing parasite infection of a plant. | 12-11-2014 |
20140378402 | Amino Sugar-Bound Anti-Cancerous Noble Metal Complex - Disclosed is a pharmaceutical composition containing as an active ingredient a compound represented by formula (I) or a physiologically acceptable salt thereof, and a method for treating cancer, the method including administering the compound represented by formula (I) or the physiologically acceptable salt thereof. | 12-25-2014 |
20150018294 | MODULATORS OF TOUSLED KINASE IN CELLULAR PROCESSES - The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides for methods and pharmaceutical agents to modulate the activity of Tousled-like kinase (TLK). The invention also provides for methods and pharmaceutical agents to inhibit the activity of Tousled-like kinase to provide increased sensitivity to irradiation (IR) and chemotherapeutic agents. The invention also provides for methods and pharmaceutical agents to increase the activity of Tousled-like kinase to provide increased protection against DNA damaging agents including to irradiation (IR) and chemotherapeutic agents. | 01-15-2015 |
20150025028 | Method for Treating Abnormal Polyglutamine-Mediated Disease - A method for treating an abnormal polyglutamine-mediated disease is disclosed, which comprises: administering a pharmaceutical composition comprising a trehalose-based compound to a subject in need. Additionally, the pharmaceutical composition optionally further comprises a trehalase inhibitor. | 01-22-2015 |
20150309022 | Synthetic Ligands for the Differentiation of Closely Related Toxins and Pathogens - Synthetic ligand compounds and methods of differentiating between Shiga toxin 1 and Shiga toxin 2 are disclosed herein. Another embodiment includes a kit for differentiating between Shiga toxin 1 and Shiga toxin 2. Assay systems and methods for providing an assay are also provided for herein. | 10-29-2015 |
20160008319 | PHARMACEUTICAL COMPOSITIONS FOR INHIBITING ANGIOGENESIS | 01-14-2016 |
20160129035 | COMBINED ANTI-ACID-FAST BACTERIAL AGENT, SCREENING METHOD FOR ANTI-ACID-FAST BACTERIAL AGENTS, AND ACTIVITY INHIBITOR OF WecA OR ORTHOLOG THEREOF - A drug combination against acid-fast | 05-12-2016 |
20160184341 | ORAL ADMINISTRATION OF ANTHOCYANINS, ANTHOCYANIDINS, AND THEIR METABOLITES FOR THE TREATMENT OF INFLAMMATION IN AN INFLAMMED JOINT - The invention provides methods of reducing inflammation and improving the catabolic/anabolic state to promote healing of the cartilage in a joint by providing an oral dosage of either an anthocyanin or an anthocyanidin or their metabolites or a combination thereof. The treatment can occur before surgery, injury or inflammation occurs as a prophylactic treatment and/or can continue during or after the surgery, injury or inflammation has begun. | 06-30-2016 |